DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "MediPoint: Viscosupplementation - North America Analysis and Market Forecasts" report to their offering.
This report analyzes and discusses the major drivers and barriers of viscosupplementation adoption, and provides an in-depth understanding of the future outlook for this market by geography, with an overall emphasis on the current and future trends in the three countries.
North American viscosupplementation market was estimated at $889.4M in 2016 across the three markets (Canada, Mexico, and US). By the end of the forecast period in 2023, it is estimated that the market will grow to approximately $1.4B at a Compound Annual Growth Rate (CAGR) of 6.4%.
Osteoarthritis (OA) constitutes a growing public health burden, and is the most common cause of musculoskeletal disability around the world. Resulting from a complex interaction of biomechanical, biochemical, and genetic factors, OA develops slowly and is characterized by the degradation of the affected joint's cartilage and bone hypertrophy. The disability is accompanied by joint pain, stiffness, and loss of range of motion. Initially treated with various therapies including physical therapy and nonsteroidal anti-inflammatory drugs (NSAIDs), advanced cases of OA have traditionally been treated surgically.
However, intra-articular viscosupplementation with hyaluronic acid (HA), a high-molecular-weight glycosaminoglycan, has become an increasingly accepted therapeutic alternative to knee replacement surgery in the symptomatic management of OA over the past decade.
The US represented the largest portion of the market in 2016, holding 95.7% of the regional revenue, and is expected to maintain this dominance through the forecast period. The US is also expected to be the fastest-growing market through 2023, at a CAGR of 6.4%, while the slowest growth will be observed in Mexico.
Key drivers of the viscosupplementation market in the forecast period are:
- The rising prevalence of osteoarthritis (OA) due to increasing aging and obese populations.
- The evolving multimodal treatment paradigm for OA.
- Patients seeking to delay knee replacement surgery in an effort to maintain an active lifestyle.
Key Topics Covered:
1 About the Authors
2 Table of Contents
3 Executive Summary
5 Market Outlook
6 Market Insights
7 Competitive Assessment
- Anika Therapeutics
- Ferring Pharmaceuticals
- Fidia Farmaceutici
- Seikagaku Corporation
For more information about this report visit https://www.researchandmarkets.com/research/mlnv5d/medipoint